Table 1 Characteristics of the included studies
Author, year of Publication | Study origin | Studies included | Participants | Cancer Group | |||||
|---|---|---|---|---|---|---|---|---|---|
Number of studies included | Type of studies included | Years of published included articles | Country of origin of included studies | Number | Socio-demographic characteristics | Cancer type | |||
James et al. (2022) [21] | London | 32 | 18 longitudinal studies, 14 a cross-sectional study | 2003 - 2021 | Europe (n=13), North America (n=11), Australia (n=6), Asia (n=2) | 9953 | Males | Prostate cancer | |
Landry et al. (2022) [22] | Canada | 25 | 16 cross-sectional, 4 cohort studies, 5 mixed methods or qualitative studies | 2003 - 2022 | Asia (n=9), Europe (n= 8), America (n=6), Africa (n=1), Oceania n=1) | 54571 | NA | DTC (differentiated thyroid carcinoma) patients | 54571 |
Wintraecken et al. (2022) [23] | Netherlands | 12 | 6 cohort studies, 6 cross-sectional studies | 2004 - 2020 | China (n=1), Germany (n=1), Italy (n=1), Netherlands (n=1), Serbia (n=1), USA (n=7) | 2729 | ≥18 years | Breast cancer | 2729 |
Rimmer et al. (2023) [24] | England | 29 | 13 cross-sectional studies, 9 longitudinal studies | 2001 - 2021 | Netherlands (n=3), USA (n=3), China (n=2), Italy (n=2), India (n=2), Japan (n=2), Norway (n=2), Australia (n=1), Finland (n=1), Germany (n=1), South Korea (n=1), Sweden (n=1), Turkey (n=1) | 2093 | Mean age range 35.8 - 49.5 years.Sex range 24 – 73 % female. | Low-grade glioma | 2093 |
Zou et al. (2022) [25] | China | 27 | 2 retrospective cohort studies, 1 retrospective case-control study, 11 cross-sectional, 11 prospective cohort studies, 1 interrupted time series, 1 case-control study | Before April 2021 | Asia (27) | 20861 | >18 years | Hepatocellular carcinoma | 20861 |
Baba et al. (2021) [26] | Morocco | 13 | 13 cross-sectional observational studies | 2009 - 2020 | Italy (n=9), France (n=2), Egypt (n=1), Turkish (n=1) | 617 | >18 years | Glioblastoma | 617 |
Min-max: 19 - 85 | |||||||||
Rupp et al. (2021) [27] | Germany | 59 | Clinical trials, registry-based studies, cohort studies, population-based studies | 1998 - 2020 | Canada (n=1), China (n=13), France (n=1), Germany (n=4), Iran (n=2), Israel (n=1), Japan (n=1), Korea (n=18), Portugal (n=1), Sweden (n=3), Taiwan (n=1), Turkey (n=1), United Kingdom (n=4), Vietnam (n=1) | 75733 | >18 years | Gastric cancer | 75733 |
Sihvola et al. (2022) [28] | Finland | 11 | 9 cross-sectional, 2 intervention (RCT) | 2014 - 2021 | Brazil (n=2), China (n=5), Israel (n=3), Turkey (n=1) | 1553 | ≥18 years | Colorectal cancer | 1553 |
Mean age: 59 years | |||||||||
Range age: 18 - 87 | |||||||||
941: male; 623: female | |||||||||
Aizpurua-Perez et al. (2020) [29] | Spain | 39 | 30 cross-sectional studies, 8 intervention study, 1 longitudinal study | 2011 - 2020 | Asia (n = 16), Europe (n = 14), America (n = 8), Oceania (n = 1) | 6189 | Age range 18 - 90 years. | Breast cancer | 6189 |
El Haidari et al. (2020) [30] | France | 33 | 28 cross-sectional, 3 case control, 2 longitudinal | 2004 - 2018 | Iran (n=15), Turkey (n=9), Saudi Arabia (n=3), Jordan (n=2), Lebanon (n=1), Kuwait (n=1), Bahrain (n=1), Yemen (n=1) | 9323 | Middle east countries | Breast cancer | 9323 |
Age range: 25 - 60 | |||||||||
Kang et al. (2020) [31] | Korea | 45 | 23 cohort studies, 13 cross-sectional studies, 9 intervention studies | 2010 - 2018 | China (n=11), USA (n=10), Taiwan (n=6), France (n=4), UK (n=2), Japan (n=5), Germany (n=2), Italy (n=2), Singapore (n=2), Hong Kong (n=1) | 6988 | Mean age 58.9 years. | Hepatocellular carcinoma | 6988 |
Odeo et al. (2020) [32] | Kenya | 54 | 21 cross-sectional studies, 13 prospective Studies, 5 prospective cohort study, 4 prospective studies, 3 retrospective studies, 2 longitudinal prospective studies, 1 longitudinal, observational study, 1 multicentre, prospective, non-Interventional trial study, 1 Phase III, RCT, 1 prospective longitudinal study, 1 cohort study, 1 longitudinal study | 2000 - 2020 | N/A | 7394 | Most participants were from Europe and America, one few studies involved participants from Asia. | Prostate cancer | 7394 |
Nierop-Van Baalen et al. (2020) [33] | Netherlands/Belgium | 33 | 28 cross-sectional, 2 prospective cohort, 2 randomized controlled trial, 1 longitudinal | 2009 - 2019 | Asia (n=14), America (n=10), Europe (n=8), Australia (n=1) | 6275 | > 18 years, under treatment | All cancer types | 3821 |
Bladder | 78 | ||||||||
Breast cancer | 996 | ||||||||
Central nervous system | 269 | ||||||||
Cervical cancer | 480 | ||||||||
Colorectal | 429 | ||||||||
Leukemia | 70 | ||||||||
Lung | 132 | ||||||||
Sousa et al. (2019) [34] | Portugal | 44 | 31 retrospective cross-sectional studies, 12 prospective studies, 1 ambispective study | 2000 - 2018 | USA (n=8), UK (n=5), Canada & USA (n=4), The Netherlands (n=3), Sweden (n=3), Canada (n=2), Korea (n=2), Ireland (n=2), Germany (n=2), Spain (n=2), France (n=2), Australia (n=2), Turkey (n=1), Poland (n=1), Norway (n=1), Italy (n=1), Denmark (n=1), Czech Republic (n=1), Brazil (n=1) | 16683 | Mean age 50.9 years. | Breast cancer | 16683 |
Ho P.J. et al. (2018) [35] | Singapore/ Netherlands | 57 | 43 cross-sectional studies and 14 longitudinal studies | 2005 - 2017 | Korea (n=17), China (n=14), India (n=8), Taiwan (n=6), Malaysia (n=6), Japan (n=5) and Thailand (n=1) | 24538 | Womenliving in Eastern Asia, South Central Asia and Southeast Asia | Breast cancer | 24538 |
Brandão et al. (2017) [36] | Portugal | 41 | 41 longitudinal studies | 2000 - 2015 | USA (n = 10), the Netherlands (n = 8), Australia (n=1), Canada(n=1), Denmark (n=1), France (n=1), Greece (n=1), Hong Kong (n=3), Iran (n=2), Japan (n=1), Norway (n=1), Portugal (n=2), Spain (n=2), South Korea (n=1), Sweden (n=2), Taiwan (n=2), United Kingdom (n=2) | 9361Sample size range 50 - 763 | Mean age 53.7 years. | Breast cancer | 9361,00 |
Razdan et al. (2016) [37] | New York, USA | 22 | 18 Case Series, 4 Prospective Cohort | 1995 - 2014 | Canada (n=3), Netherlands (n=3), Norway (n=1), Sweden (n=8), Turkey (n=1), UK (n=1), USA (n=5) | 2046 | Women | Breast | 2046 |
Bai et al. (2015) [38] | USA | 36 | 32 cross-sectional studies, 4 longitudinal studies | 1996 - 2014 | USA (n=27), Jordan (n=2), Australia (n=2), The Netherlands (n=1), Canada (n=1), Iran (n=1), Italy (n=1), Japan (n=1) | 18948 | N/A | All cancer types (8 studies targeted breast cancer, prostate or colorectal) | 18948 |